- Benzinga•20 hours ago
Cantor Fitzgerald analysts maintain their Buy rating on Omeros Corporation (NASDAQ: OMER ) after promising OMS721 data in kidney disorders and associated improvement of thrombotic microangiopathies (TMA) ...
- Business Wire•yesterdayOmeros Announces Positive Data from OMS721 Phase 2 Trial in Patients with Stem Cell Transplant-Associated Thrombotic Microangiopathy
Omeros Corporation today announced positive results in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy from the company's Phase 2 clinical trial of OMS721 in TMAs, with clinically meaningful improvement in measures of red blood cell destruction, specifically lactate dehydrogenase and haptoglobin levels .
LONDON, UK / ACCESSWIRE / October 20, 2016 / Active Wall St. blog coverage looks at the headline from Omeros Corp. (NASDAQ: OMER ) as the company announced positive results from a Phase 2 clinical trial ...
Omeros Corporation (OMER)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
|Bid||8.44 x 100|
|Ask||8.45 x 100|
|Day's Range||8.20 - 8.71|
|52wk Range||7.20 - 16.80|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-4.45|
|Avg Vol (3m)||449,101|
|Dividend & Yield||N/A (N/A)|